Impact of nivolumab monotherapy infusion time-of-day on short- and long-term outcomes in patients with metastatic gastric cancer
Our data suggest that scheduling nivolumab infusions before mid-afternoon should be considered in daily practice for the treatment of mGC.
Authors
- Hiroya Taniguchi
- Yasunobu Ishizuka (ORCID: https://orcid.org/0009-0003-3305-4013)
- Yukiya Narita
- Kei Muro
- Masashi Ando
- Toshiki Masuishi (ORCID: https://orcid.org/0000-0002-7521-1596)
- Masahiro Tajika (ORCID: https://orcid.org/0000-0002-3761-6971)
- Kazunori Honda (ORCID: https://orcid.org/0000-0001-5090-9771)
- Shigenori Kadowaki (ORCID: https://orcid.org/0000-0001-9923-5309)
- Tomoki Sakakida (ORCID: https://orcid.org/0000-0003-1913-7923)
- Hiroko Kodama (ORCID: https://orcid.org/0009-0003-4548-4109)
- Munehiro Wakabayashi (ORCID: https://orcid.org/0009-0001-8844-6845)
Institutions
- Aichi Cancer Center (JP)
Publication Details
- Journal
- Therapeutic Advances in Medical Oncology
- Published
- 2025-01-01
- DOI
- https://doi.org/10.1177/17588359251339921
- Citations
- 2
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 2.09